Skip to main content
Premium Trial:

Request an Annual Quote

Tripos, Vector Capital, Cognia, University of Helsinki, Tooltech Software, EBI, BioWisdom, Critical Path Institute, Rosetta Biosoftware, Bristol-Myers Squibb, Golden Helix, United Devices, Gene Company, Partek, Biozentrum, GeneBio

Tripos Wraps up Sale of Discovery Informatics to Vector Capital
Tripos this week completed the sale of the assets of its Discovery Informatics business to private equity boutique Vector Capital.
Vector paid Tripos $26.2 million for the business — an increase of around $575,000 over the $25.6 million purchase price that the companies initially agreed to in November [BioInform 11-27-06].
Tripos said that the price increase was due to “improved working capital of the business since the signing of the asset purchase agreement.”
Tripos used around $8.5 million of the proceeds to repay a loan to LaSalle Bank.
Tripos said in an 8-K filing that it expects liquidation of its remaining assets to occur in around six months. The company added that it is still trying to sell its Discovery Research business, “although no assurance can be given that a transaction for this division can be completed on satisfactory terms.”

Cognia Licenses ITI Text-Mining Technology, Plans Expansion
Bioinformatics database developer Cognia said this week that it has licensed text-mining technology from ITI Life Sciences, a Scottish economic development organization.
Cognia has the right to use the technology in life science applications, while ITI retains rights to other vertical markets.
Cognia’s European branch, Cognia EU, which is based in Edinburgh, co-developed the technology with the University of Edinburgh’s School of Informatics.
Under the agreement, ITI will receive royalties from sales of the resulting product. ITI said these proceeds will be re-invested in the ITI Life Sciences Text Mining research program, a three-year initiative that is scheduled to end in one year.
Cognia said it can deploy and commercialize the IP immediately, and said it expects to create “numerous databases” from the text-mining program.
Bob Merold, president and CEO of Cognia, told BioInform via e-mail that the original agreement with ITI “was to provide service work to them in constructing text-mining IP, working closely with experts at University of Edinburgh’s Natural Language Laboratory.”
The project “has made enough progress that we have taken an interim license to the IP to deploy now, even before the program is complete,” Merold said. “We expect to do a permanent license later in the year when we know the exact scope of the final IP deliverable.”
Separately, Cognia announced that it plans to create a new “operations center” for its text-mining activities in Edinburgh that will house a larger number of curators.
The company opened the center in March 2005 with 30 employees. Merold said that the center currently employs about 50 people and the target for the end of the year is 75.

University of Helsinki, India’s Tooltech Form Bioinformatics Firm
The University of Helsinki said this week that it is partnering with Indian IT firm Tooltech Software to create a bioinformatics services company called Systems Biology Worldwide.
The new company will be based in Bangalore, India and will offer analytical services and software, the university said.
“We will process Finnish bioscientific information with lower costs in India and sell it globally,” said Tooltech CEO Atul Khanna in a statement.
Khanna is chairman of the board in the new company, while Juha Eväsoja, formerly the marketing manager for IBM Life Sciences in Finland, will serve as CEO.
The company will employ “a few dozen” staffers in India and about a dozen in Helsinki.

EBI to Use BioWisdom’s SRS 8.2
BioWisdom said this week that the European Bioinformatics Institute has signed a site license agreement for SRS 8.2.
The EBI’s External Services group will use the upgraded version of the software in its services offering, BioWisdom said.
Financial terms of the agreement were not provided.

C-Path Using Rosetta's Resolver in Predictive Safety Testing Consortium
The Critical Path Institute will use Rosetta Biosoftware’s Resolver system, Rosetta said this week.
C-Path will use the software for data management and analysis in the Predictive Safety Testing Consortium, a collection of pharmaceutical companies working with C-Path to share biomarker information.
C-Path is a publicly funded research and education institute in Tuscon, Ariz., and is a research arm of the US Food and Drug Administration’s Critical Path Initiative.
Financial terms of the deal were not released.

BMS Adopts United Devices Desktop Grid …
United Devices said this week that it is building a high-performance computing system for Bristol-Myers Squibb that will include the company's HPC clusters and desktop PCs.
The agreement includes UD solutions and services, including the company’s UD Cluster Scheduler and PC Grid infrastructure, but further details were not released.
UD said it has completed initial installation at BMS and will deliver additional capabilities over the next several months.
The company claimed that seven of the top 10 global pharmaceuticals are now using UD systems.

… as Golden Helix Agrees to Run its Software on United Devices’ Platform
United Devices and Golden Helix said this week that they will partner to make two of Golden Helix’s genomics software applications interoperable with United Devices’ Grid MP software.
Under the agreement, Golden Helix’s Helix Tree and PBAT analysis platforms, which are used in genome-wide association studies, will be integrated with United Devices’ grid system to enhance their capacities and speed, the companies said.

Gene Company to Distribute Partek's Software in China
Partek said this week that Gene Company will distribute its software in China.
Under the agreement, Hong Kong-based Gene Company will sell, market, and support Partek’s Genomics Suite, Discovery Suite, QSAR Solution, and the Partek Screening Solution.

Biozentrum to Use GeneBio's Phenyx in Proteomics Cluster
Biozentrum, a research institute at the University of Basel, will integrate Geneva Bioinformatics’ Phenyx mass spec analysis software into its proteomics cluster, GeneBio said this week.
Biozentrum will use Phenyx as its “primary search engine,” GeneBio said.
The company said that it will customize scoring schemes for Biozentrum’s equipment.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.